Immunetune joins the fight against Sars-CoV-2

May 7, 2020

Within a newly established consortium, Immunetune will develop enhanced DNA vaccines against SARS-CoV-2 and other human coronaviruses. The vaccine is built on the combination of two strong synthetic vaccine platforms and the inclusion of conserved T and B cell epitopes to provide both humoral and cellular defenses against Covid-19 and possible future outbreaks of coronaviruses. The consortium is financially supported by Health Holland.

Biotechgate Digital Partnering 31 Aug – 3 Sep 2020

Biotechgate Digital Partnering 31 Aug – 3 Sep 2020

Roger Legtenberg, CBO of Immunetune, will attend the Biotechgate Digital Partnering event on 31 Aug - 3 Sep, 2020. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.

read more